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A successful outcome to pregnancy is dependent on the ability of the maternal uterine
microenvironment to regulate inflammation processes and establish maternal tolerance.
Recently, B cells have been shown to influence pregnancy outcomes as aberrations in
their numbers and functions are associated with obstetric complications. In this study,
we aimed to comprehensively examine the population frequency and phenotypic profile
of B cells over the course of murine pregnancy. Our results demonstrated a significant
expansion in B cells within the uterus during the peri-implantation period, accompanied
by alterations in B cell phenotype. Functional evaluation of uterine B cells purified from
pregnant mice at day 5.5 post-coitus established their regulatory capacity as evidenced
by effective suppression of proliferation and activation of syngeneic CD4+ T cells. Flow
cytometric analysis revealed that the uterine B cell population has an expanded pool
of IL-10-producing B cells bearing upregulated expression of co-stimulatory molecules
CD80 and CD86 and activation marker CD27. Our investigations herein demonstrate
that during the critical stages surrounding implantation, uterine B cells are amplified and
phenotypically modified to act in a regulatory manner that potentially contributes toward
the establishment of maternal immunological tolerance in early pregnancy.
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INTRODUCTION
Pregnancy is a model of immune tolerance wherein the mother carries a semi-allogeneic fetus that
in principle triggers a maternal immune response due to the presence of paternally derived fetal
alloantigens; however the inflammation is kept at a tolerable level and the pregnancy progresses.
In early pregnancy, it is well-accepted that for implantation to occur, a regulated pro-inflammatory
microenvironment that permits tissue remodeling and angiogenesis at the maternal-fetal interface
is required. This is then followed by a shift to an immune tolerogenic profile that allows for fetal
growth and development (1, 2). The necessity of a controlled inflammatory environment during
this time implies a dynamic feto-maternal crosstalk of immune, endometrial, and fetal cells. A
multitude of preclinical and clinical pregnancy studies show immune cells such as uterine dendritic
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cells, decidual macrophages, decidual natural killer cells, and
regulatory T cells undergo changes during pregnancy for the
purposes of calibrating inflammation and mediating maternal
immune tolerance (3). For B cells, their role in the induction
of maternal immune tolerance in pregnancy to date remains
poorly understood.
Although studies on B cells in pregnancy are limited, there
is an emerging view of their involvement in the physiology
of pregnancy. Studies on murine models have demonstrated
that percentages of B cell subsets are altered throughout
gravidity. In the bone marrow and the spleen, murine B
cells undergo lymphopenia mid-pregnancy as numbers of bone
marrow pre/pro and immature B cells as well as splenic
follicular B cells drop substantially at day 14 post-coitus (4).
However, splenic marginal zone B cells and mature B cells
in the para-aortic lymph nodes that drain the uterus were
also reported to expand (4, 5). A normal pregnancy was also
associated with an enhanced production of immunoglobulins
by marginal zone B cells, speculated to reduce the occurrence
of autoreactive B cells that may cause pregnancy complications
(5). Similarly, changes in the proportions of B cell subsets
during pregnancy have been documented in the clinical setting.
Analysis of peripheral blood showed a significant decrease in the
percentages of CD19+CD24brightCD38bright transitional B cells
during normal pregnancy and relatively higher percentages of
non-switched memory B cells were associated with recurrent
miscarriages (6, 7).
Recently, there has been interest in B cells taking on a
regulatory role during pregnancy as a specific subset of B
cells called “regulatory B cells” or Bregs have been implicated
in the network of immune cells crucial for maintaining
pregnancy. Interestingly, Bregs do not have a specific phenotypic
marker, rather they are defined by their functional capacity
for suppressing other immune cells (8). Among the known
Breg subtypes, IL-10-producing B cells or B10 cells are
the most commonly studied. Adoptive transfer of B10 cells
induced from splenic B cells was previously shown to restore
tolerance and rescue pregnancies in abortion-prone mice (9).
Peritoneal CD19+IL-10+ cells were also shown to increase
throughout normal pregnancy whereas a significant reduction
was seen in abortion-prone pregnant females (10). Additionally,
clinical studies correlate inadequate number of circulating
IL-10-producing CD24hiCD27+ B cells with higher risk of
spontaneous abortion (11). These studies however have been
restricted to B cells in the spleen, peritoneum, and in the
blood while studies of B cell function within the pregnancy
microenvironment is noticeably lacking. The main hindrance
to studying the B cells in the uterine mucosa and the
decidua stem from the paucity of B cells within these tissues.
Uterine cell profiling of the murine estrous cycle showed
that B cells constituted 1.5% of viable cells at estrus (12). In
humans, B cells are considered rare lymphocyte subpopulations
in the uterus with a median of 2% in pre-implantation
uterine tissue and 5% in the decidua (13, 14). Moreover,
the functional promiscuity of B cells also poses an added
layer of complexity in describing the specific role of B cells
in pregnancy.
In the present work, we used a murine C57Bl/6J x BALB/c
semi-allogeneic pregnancy model to describe the phenotypes
and functions of B cells within the uterine microenvironment
throughout gestation. Our results indicate that these uterine B
cells undergo changes in frequency and phenotype, particularly
during the peri-implantation phase of pregnancy between
days 2.5 and 8.5 post-coitus (pc). B cells were shown to be
significantly expanded as well as express markers and cytokines
indicative of regulatory qualities. Furthermore, we show in ex
vivo experiments that uterine B cells collected from pregnant
females at day 5.5 pc significantly suppressed proliferation and
activation of syngeneic CD4+ T cells via cell-cell interactions.
We thus posit that uterine B cells at peri-implantation exhibit
immunosuppressive characteristics and likely take part in




All mice were housed in a specific-pathogen free (SPF) animal
facility with optimal lighting and food and water ad libitum.
Female C57Bl/6J mice (6–9 weeks of age) were checked for
estrous cycle stage by vaginal flushing with 20 µL sterile
PBS and assessing the types and ratios of cells present by
bright field microscopy. Females in proestrus or early estrus
stages were placed with a BALB/c stud for mating overnight.
The following day, female mice were visually inspected for
the presence of a vaginal copulation plug indicative of a
successful mating event. This was designated day 0.5 post-coitus
(d0.5 pc). Virgin age-matched females at estrus were used as
experimental controls.
Tissue Dissociation and Cell Purification
At time points indicated for each experiment, the following
organs were collected: spleen, the uterus draining para-aortic
lymph nodes (PALNs), and uterus.
Single cell preparations from the spleen and lymph nodes
were isolated by standard methods. Briefly, using the plunger
of a small syringe, spleens, or lymph nodes were crushed
through a 70µm cell strainer. The resultant single cell
suspension was spun (300 × g, 5min), and resultant pellet
resuspended in 1mL of ammonium-chloride-potassium
(ACK) lysis buffer for 5min to eliminate red blood cells.
RPMI culture medium supplemented with 2% fetal bovine
serum (FBS) was then added to neutralize the lysis buffer.
Splenocytes were washed twice with PBS, and resuspended at
107 cells/mL.
Cells were extracted from uterine tissue using the
gentleMACSTM Octo Dissociator (Miltenyi Biotec, Bergisch
Gladbach, Germany). Uterine tissue was dissected into small
pieces then transferred into gentleMACSTM C tubes suspended
in RPMI culture medium supplemented with Collagenase
A (10 mg/mL, Roche, Basel, Switzerland) and DNAse I
(280U per sample, Sigma-Aldrich, MO, USA) for efficient
connective tissue digestion. Heating adaptors were used
for optimal temperature control of tissue dissociation. The
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resultant homogenized tissue suspension was passed through
a 70µm cell strainer, resuspended in culture medium and
washed twice with PBS. Collected cells were resuspended
at 107 cells/mL.
In experiments requiring B or T cells, the harvested
mixed cells were further purified by magnetic isolation. B or
T cells were negatively selected for using the MojoSortTM
Mouse Pan B Cell Isolation Kit (480052; Biolegend,
San Diego, CA, USA) or MojoSortTM Mouse CD4T
Cell Isolation Kit (480033; BioLegend) according to the
manufacturer’s instructions. Isolated B cells or CD4+ T cells
were routinely achieved >90% purity as assessed by flow
cytometry (Supplementary Figure 1).
For uterine tissue, the resultant cell suspension was briefly
incubated with anti-mouse CD16/32 (FC block; eBioscience,
San Diego, CA, USA) for 15min at 4◦C to block Fc receptors,
washed, then stained with conjugated monoclonal antibody anti-
mouse CD19-APC-Cy7 (BD Biosciences, NJ, USA) for 40min
in the dark on ice. CD19+ B cells were subjected to more
restrictive FSC-W × FSC-H and SSC-W × SSC-H assessment
to ensure single cells were purified by sorting on a FACS Aria
II (BD Biosciences). A 100µm nozzle at a flow rate of 2,000
events/s generated a sorting efficacy between 95 and 100%.
Sorted uterine CD19+ B cells were used in the suppression assay
described below.
Phenotypic Analysis by Flow Cytometry
Multi-parameter flow cytometry was used to identify the
expression of B cell phenotype markers in cells isolated
from the organs of interest. Harvested cells were collected,
washed, and then incubated with anti-mouse CD16/32 for
15min on ice. After washing once, cells were stained with
a cocktail of monoclonal antibodies diluted in buffer for
40min. Rat/Armenian hamster anti-mouse monoclonal
antibodies used are as follows: CD19-APC-Cy7 (1D3; BD
Biosciences), B220-APC (RA3-6B2; BioLegend), CD1d-
FITC (1B1; BD Biosciences), CD5-BV510 (53-7.3; BD
Biosciences), CD38-BV421 (90/CD38; BD Biosciences),
CD138-BV510 (281-2; BD Biosciences), TIM-1-BV421 (RMT
1-4; BD Biosciences), PD-L1-PE-Cy7 (MIH5; eBioscience),
CD80-PE-Cy7 (16-10A1; BioLegend), CD86-AF488 (GL-1;
BioLegend), CD21-BV421 (7E9; BioLegend), CD24-BV421
(M1/69; BioLegend), CD27-PE-Cy7 (LG.3A10; BioLegend),
I-A/I-E-AF488 (M5/114.15.2; BioLegend), IgM-AF488 (RMM-
1; BioLegend), and IgD-PE-Cy7 (11-26c.2a; BioLegend).
Stained cells were washed twice with PBS then further stained
with a fixable viability dye (eFluorTM 660; eBioscience)
for 20min and washed with PBS prior to flow cytometric
analysis (Cytoflex; Beckman Coulter, Brea, CA, USA). Post-
acquisition analysis was carried out using Kaluza analysis
software (Beckman Coulter). Unstained and single color controls
were used to set gates and identify the positive population
(Supplementary Figure 2).
Phenotypes of B cell subsets were identified as follows:
CD19+B220+CD80+CD86+ activated B cells, CD19+B220+
CD21+CD27+ memory B cells, CD19+B220+CD27hiCD38+
CD138+ plasmablasts, and CD19+B220+CD24+IgMhiIgDlo
transitional B cells.
In vitro Suppression Assay
To examine the suppressive activity of B cells collected from
pregnant or virgin mice on CD4+ T cells, B cells from the spleen
and PALNs and T cells from a syngeneic spleen were purified by
magnetic isolation while B cells from the uterus were purified by
FACS sorting. Purified CD4+ splenic T cells were labeled with
Cell Proliferation Dye e450 (eBioscience) for 10min at 37◦C in
the dark, then washed with 10% cold RPMI culture medium
twice before resuspending in pre-warmed 10% RPMI culture
medium supplemented with IL-2 (10 ng/ml, Peprotech, NJ, USA)
and DynabeadsTM mouse T-activator CD3/CD28 (eBioscience)
for T cell expansion and activation. Cells were then dispensed
into a 96-well round-bottom plate at 1 × 105 cells/well, with
purified B cells subsequently added to a final ratio of 0.5:1,
1:1, and 2:1 relative to T cell numbers, with unstimulated
T cells and T cells with Dynabeads alone as controls. After
3 days in culture, cells were analyzed using flow cytometry
to determine T cell proliferation as indicated by sequential
dye dilution.
T cell proliferation was expressed as the proliferative index
(PI) (15). The PI denotes the total number of divisions divided
by the number of cells that went into division, and is calculated
using the following formula:
PI =







)+ ...( nGn2x )]
where n = number of cells in each fluorescent peak, with the
peaks identified as follows: “pp” refers to the parental undivided
peak of T cells, “G1” is the first T-cell division peak, “G2”
the second, “G3” the third etc. until peak differentiation is not
discernible from the background fluorescence. The PI for each
sample was calculated using the fitting and modeling processes
of the software FCS Express on cell division profiles (DeNovo
Software, California, USA).
Activation of proliferating CD4+ cells was assessed by staining
with CD4-FITC (RM4-5; eBioscience) and CD25-APC (PC61.5;
eBioscience) antibodies for 40min in the dark on ice and
assessing expression by flow cytometric methods. Unstained,
single-color controls, and FMOs were used as gating controls.
Intracellular Staining of IL-10+ B Cells
Single cell suspensions were incubated for 5 h in a stimulation
cocktail [50 ng/mL phorbol-myristate-acetate (PMA); 500 ng/mL
ionomycin; 5µg/mL lipopolysaccharide (LPS 0111:B4, Sigma)]
and 1µg/mL Brefeldin A, to induce cytokine production and
inhibit Golgi transport enabling accumulation of cytokines
within the cell. Cells were then washed twice and incubated
with anti-mouse CD16/32 (eBioscience). Cells were washed once
and stained with anti-mouse B220/CD45R-BV650 (RA3-6B2; BD
Biosciences) for 40min in the dark on ice. Post-staining, cells
were fixed and permeabilized using the BD Fix/Perm Kit (BD
Biosciences) as per manufacturer’s instructions. Permeabilized
cells were incubated with PE anti-mouse IL-10 (JES5-16E3;
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BioLegend) or isotype control PE Rat IgG2b κ (RTK4530;
BioLegend) for 40min at room temperature. Lastly, cells
were washed twice with Perm Buffer, resuspended in FACS
buffer, and analyzed for B220+IL-10+ cells via flow cytometry.
Matched isotype controls were used to ensure correct gating for
IL-10+ cells.
Generation of Induced IL-10+ B Cells
Splenic B cells were magnetically isolated as above and cultured
with purified anti-mouse CD40 (HM40-3; BD Biosciences) for
48 h as previously described (16). The cell culture supernatant
was also collected and used for themeasurement of secreted IL-10
levels by ELISA.
FIGURE 1 | Proportions of uterine B cells expand significantly at peri-implantation. (A) Flow cytometric gating strategy used to identify B cells in the isolated cell
suspensions from spleen, para-aortic lymph nodes, and the uterus taken at day 5.5 pc. Single viable lymphocyte cells were gated as per exclusion of the viability dye,
FSCvSSC plots showing lymphocyte population, doublet discrimination, and single color controls. (B) Graphical summary of the percentages B220+ B cells in the
viable lymphocyte cell populations obtained from estrus and mated mice at various days pc (n = 4–9 per time point). Data is shown as mean ± SEM and compared
by one-way ANOVA, followed by Dunnett’s post-hoc multiple comparisons test. *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001.
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IL-10 Detection by ELISA
IL-10 quantities in supernatants were measured using the ELISA
MaxTM Standard Set Mouse IL-10 Kit (Biolegend) following the
manufacturer’s instructions. Briefly, high-binding 96-well plates
were coated with 100 µL of the capture antibody and kept at 4◦C
overnight. After washing, the wells were blocked with 200 µL
of 1% BSA-PBS for an hour. Samples and standards were added
and incubated for 3 h, washed, and 100 µL of biotin-conjugated
anti-IL-10 antibodies added. After washing, avidin-horseradish
peroxidase (HRP) was added for 30min. Wells were washed and
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate solution added
for 30min for colorometric detection of IL-10. The reaction was
stopped with 100 µL of 1M HCl, and plates read at 450 nm
with a differential filter set at 570 nm using the MultiSkanTM FC
(Thermo Fisher Scientific, USA) plate reader.
Statistical Analysis
All experiments were performed at least in triplicate. The results
were analyzed for significant differences using the Student’s
t-test or the Mann-Whitney test for parametric and non-
parametric samples, respectively. For multiple comparisons, one-
way ANOVA with Dunnett’s post-hoc test was used. Differences
between groups were considered statistically significant at p <
0.05 as analyzed using GraphPad Prism 7.03 software (GraphPad,
San Diego, CA, USA).
RESULTS
B Cell Proportions Are Increased in the
Uterine Tissue at Peri-Implantation
To investigate the impact of pregnancy on B cell populations
throughout gestation, we used a murine model of allogeneic
mating where C57Bl/6J females were mated with BALB/c male
studs. The percentages of B220+ B cells in the spleen, para-
aortic (uterine draining) lymph nodes, and the uterus itself were
determined at succeeding time points and compared to basal
B cell numbers found in comparable organs of virgin female
controls at estrus.
Representative flow cytometric panels indicating the gating
strategy and cell surface staining of viable B220+ B cells found
within the spleen, para-aortic lymph nodes, and uterus organs
at day 5.5 pc are shown in Figure 1A. Kinetic assessment of
organ B cells clearly showed the induction of lymphopenia
in the spleen commenced mid-pregnancy, around day 12.5 pc
(Figure 1B, left panel), with a contrasting significant increase in
B cells in the uterine draining lymph nodes occurring around day
14.5 pc (Figure 1B, middle panel), results that concurred with
data shown in previous studies (4). In the uterus however, a
statistically significant increase in B cell proportions commenced
pre-implantation, at day 2.5 pc, and continued post-implantation
to day 8.5 pc (Figure 1B, right panel). This increase in uterine
B220+ B cells was limited to this peri-implantation phase as
FIGURE 2 | B cell subsets in the para-aortic lymph nodes and uterus are altered post-implantation. Percentages of transitional or mature naive B cells
(CD24+ IgMhi IgDlo), memory B cells (CD21+CD27+), plasma B cells (CD27+CD38+CD138+), and activated B cells expressing co-stimulatory molecules
(CD80+CD86+) were investigated in the spleen, para-aortic (uterus draining) lymph nodes, and uterus of virgin and pregnant mice at day 5.5 pc (n = 6, p-values
calculated by unpaired t-test). *p ≤ 0.05.
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assessment of later time points revealed similar B cell frequencies
to that of virgin mice in estrus. Based on these results, we focused
on the day 5.5 pc time point, i.e., just after implantation, for all
subsequent analyses.
Alterations in B Cell Subsets During the
Peri-Implantation Stage of Pregnancy
Assessment of B cell subsets from spleen, uterus draining
lymph nodes, and the uterus itself at day 5.5 pc indicated
that proportions of CD24+IgMhiIgDlo transitional B cells and
CD21+CD27+ memory B cells remained the same as those
obtained from virgin female controls (Figure 2). In contrast,
levels of CD27+CD38+CD138+ plasma B cells decreased only in
the uterine tissue, with no observed changes in the spleen and the
para-aortic lymph nodes. However, CD80+CD86+ activated B
cells were found to be significantly higher in both the uterus and
the para-aortic lymph nodes at day 5.5 pc. Together this suggests
that expanded numbers of B cells at the site of implantation, and
associated draining lymph nodes, are activated and upregulate
co-stimulatory markers indicative of an increased capacity to
interact and engage with other immune cells.
Uterine B Cells From Pregnant Mice
Suppress CD4+ T Cell Proliferation and
Activation
Given the observed changes in B cell percentages and subset
composition, we hypothesized that the upregulated expression
of co-stimulatory molecules CD80 and CD86 in uterine B cells
prompted a directed engagement with T cells. Potentially, co-
stimulation of T cells by B cells is a pathway for T cell activation
that directly affects their rate of proliferation. Thus, we sought
to examine whether uterine B cells influenced CD4+ T cell
activation and proliferation.
Uteri from day 5.5 pc pregnant and virgin non-pregnant
control mice were collected and processed for single cell
suspensions. Viable CD19+ B cells sorted from the uterine cell
FIGURE 3 | Uterine B cells from pregnant mice post-implantation suppress CD4+ T cell proliferation and activation. (A) Schematic diagram of the suppression assay
used to assess the effect of B cells on CD4+ T cell proliferation and activation. (B) Representative flow cytometric panels illustrating the inhibitory effect of B cells on T
cell proliferation quantified via calculation of individual proliferation index (denoted as PI). (C) Graphical summaries of biologically independent experiments assessing
amount of CD4+ T cell proliferation and CD25 expression with and without co-culture of increasing ratio of uterine B cells. (D) The same experiments as in (C) except
T and B cells were kept physically apart by a 0.4µm transwell membrane (n = 3–8). Data is presented as mean ± SEM and compared by one-way ANOVA followed
by Dunnett’s post-hoc test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Data were combined from five independent experiments.
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FIGURE 4 | An expanded pool of IL-10+ B cells are present in the uterus after implantation. (A) Known regulatory B cell subsets were analyzed from B cells collected
from non-pregnant and pregnant uteri (n = 6–7, unpaired t-test). (B) IL-10 production by stimulated populations of purified B cells obtained from the spleen, virgin
uterus, day 5.5 pc uterus, or in vitro induced Bregs was assessed by ELISA. Data represent pooled supernatants of duplicate wells from three independent
experiments. Data is presented as mean ± SEM and compared by one-way ANOVA, followed by Dunnett’s post-hoc multiple comparisons test against unstimulated
control. *p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001. Additional Dunnett’s analysis assessed against non-pregnant virgin uterus reveal a significant increase in IL-10
produced by day 5.5 pc uterine B cells and iBregs (#p ≤ 0.05, ####p ≤ 0.0001).
suspensions were co-cultured with syngeneic TCR-stimulated
CD4+ splenic T cells for 72 h, after which the T cells were
assessed for cell proliferation and activation by upregulation of
CD25 expression (Figure 3A). Representative histograms of T
cell proliferation from unstimulated and stimulated controls,
and T and B cell co-cultures are shown with corresponding
proliferation index (Figure 3B). Combined results clearly
indicated the ability of uterine B cells from pregnant mice
to significantly inhibit the proliferation of syngeneic CD4+
T cells in a dose-dependent manner, with the proliferation
indices significantly decreased in response to an increase in
ratio of uterine B cells to T cells (Figure 3C, left panel).
Similarly, inhibition of proliferation was also associated with
decreased numbers of CD4+ T cells expressing the activation
marker CD25 (Figure 3C, right panel). Furthermore, this
inhibitory ability of B cells from pregnant mice was tissue-
specific, as no inhibitory capacity was observed by B cells
obtained from the spleen or uterus-draining lymph nodes in
the same pregnant mice (Supplementary Figure 3A). B cells
obtained from virgin control mice could only inhibit T cell
proliferation and activation at the highest ratio of B:T cells
(2:1) indicating that pregnancy amplified this basal uterine B
cell response.
To determine whether the inhibitory effect was evoked by B-T
cell cognate interactions or via soluble molecules produced by
B cells, we conducted the same experiment but with the B cells
and T cells physically separated by a 0.4µm transwell membrane.
No significant increase in inhibition of proliferation or CD25
activation was observed (Figure 3D; Supplementary Figure 3B),
which suggested that the suppressive effect of uterine B cells on
T cells is mediated by cognate cell-to-cell interactions rather than
through soluble mediators.
Uterine B Cells at Peri-Implantation Stage
Exhibit an Enhanced Regulatory Phenotype
The previous results indicated that uterine B cells exhibited a
suppressive phenotype at day 5.5 pc, post-implantation. We next
sought to investigate whether these uterine B cells possessed
surface and functional markers typically seen in Bregs such as
the expression of TIM-1, PD-L1, CD1d, CD5, as well as the
anti-inflammatory cytokine IL-10 (8).We focused particularly on
investigating if there were differences in the frequencies of these
known Breg phenotypes between uterine B cells from virgin mice
and uterine B cells from pregnant mice that could account for
their differing effects on CD4+ T cells.
Assessment of surface markers indicated statistically
similar proportions of TIM-1+ B cells, PD-L1+ B cells, and
CD1dhiCD5+ B cells within the uterus of virgin and pregnant
mice. In contrast, IL-10 cytokine expression in uterine B cells
was found to be significantly increased after implantation
(Figure 4A). Furthermore, ex vivo stimulated uterine B cells
at day 5.5 pc produced levels of IL-10 that were significantly
higher than unstimulated controls, stimulated splenic B cells,
and stimulated uterine B cells from virgin mice, although
levels are 4–5-fold less than the amount of IL-10 produced by
the positive control, in vitro generated splenic IL-10+ B cells
(Figure 4B). These results indicated that the capacity of uterine
B cells from pregnant mice to regulate T cell proliferation and
activation may be due to a significant increase in the proportion
of IL-10-producing B cells within the uterine B cell population.
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FIGURE 5 | IL-10+ B cells at day 5.5 pc have upregulated expression of CD27, CD80, and CD86. (A) Gating strategy for IL-10+ cells within the viable CD19+ cell
population. (B) Representative flow cytometric profiles of B10 cells (blue) and IL-10− B cells (purple) and their upregulated expression of activation marker CD27 and
co-stimulatory molecules CD80 and CD86, and the corresponding graphical presentation of the mean fluorescence intensity (MFI) of B10 cells compared to IL-10− B
cells by unpaired t-test. *p ≤ 0.05, ****p ≤ 0.0001. Data shown are from three independent experiments.
Phenotype Profile of Uterine IL-10+ B Cells
at Peri-Implantation Show Increased
Activation and Co-stimulatory Markers
Phenotypic analysis of uterine B cells, as identified by their
expression of CD19 and B220, showed that at day 5.5 pc they
co-expressed two B cell receptor isotypes IgM and IgD, as well
as major histocompatibility complex class II (MHC class II),
signifying their antigen-driven development and maturity, as
well as their capacity to act as professional antigen-presenting
cells. These cells also expressed CD24, CD21, and CD38,
surface markers associated with B cell differentiation and
activation (Supplementary Figure 4). However, multi-parameter
flow cytometric analysis of uterine IL-10+ B cells (Figure 5A),
indicated that these cells expressed higher levels of co-stimulatory
molecules CD80 and CD86 compared to non-IL-10 expressing
B cells. Notably, expression of activation marker CD27 was
also significantly increased in uterine IL-10+ B cell cells
(Figure 5B). The differential expression of thesemarkers suggests
the involvement of uterine IL-10+ B cells in regulation of
the maternal immune response at implantation, particularly
through their increased capacity to engage and interact with
T cells. Together with the previous findings, we posit that
the enhanced expression of these co-stimulatory and activation
markers accompanied with the increased production of anti-
inflammatory IL-10, enable uterine B cells to regulate the
proliferation and activation of CD4+ T cells.
DISCUSSION
B cells are a major component of the lymphoid immune system.
Their functional promiscuity is due to the variety of B cell subsets
that can carry out one or more functions such as antibody
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production, antigen presentation, or secretion of modulatory
cytokines. Historically, B cells in pregnancy and early life have
been poorly studied due to their scarcity in the pregnancy
microenvironment. However, studies over the past decade have
only strengthened the need to explore the role of B cells in
gestation as links between B cell abnormalities and obstetric
complications have been repeatedly shown (17–19).
Variations in frequency and modification in phenotype
and function have been demonstrated in maternal B cells
from the bone marrow and spleen during murine pregnancy,
but examination of the B cell compartment within the
uterine microenvironment remains limited. As the molecular
architecture and function of B cells are heavily influenced by the
extracellular environment and their exposure to foreign antigens
(20), we hypothesized that B cells within uterine tissue in close
proximity to the implanting semi-allogeneic embryo undergo
changes in phenotype and function to support the development
of maternal-fetal tolerance. In this study, we investigated the
modifications in B cells, particularly within the uterine mucosa,
in amouse allogenic pregnancymodel to provide a clearer picture
of the role they play during early pregnancy.
Assessment of B cell proportions in the spleen over the
gestational period recapitulate the B cell lymphopenia previously
reported at mid-gestation (4). However, we also show a
significant expansion in B220+ cells in the uterus over the peri-
implantation period (days 2.5–8.5 pc; Figure 1). This expansion
at the time points approaching, during, and post-implantation,
suggests their involvement in the control of the inflammation
required for successful decidualization and implantation. At
the peri-implantation period, the morphologic and functional
changes in the endometrium are accompanied by major changes
in the proportion and number of endometrial immune cells
(21, 22). Uterine dendritic cells, decidual macrophages, and
regulatory T cells are some of the immune cells recruited into the
endometrium to accumulate around the embryo at implantation
(23–25). Alteration in the number and function of these cells
in the local pregnancy milieu has been demonstrated to be
instrumental in the recognition of fetal alloantigens, decidual
differentiation, and the establishment of maternal immune
tolerance (21, 22). Recently, we have shown in vitro that human
trophoblasts can educate B cells to acquire regulatory properties
that protect against T cell-mediated inflammation that may
otherwise be detrimental to implantation (26). Our results herein
showing the expansion of B cells in the murine pregnancy
microenvironment further suggest an intimate involvement of
B cells in facilitating induction of immune tolerance during the
peri-implantation phase of pregnancy.
Focusing on the peri-implantation time point at day 5.5 pc
(Figure 2), we showed the pregnant uterus harbors a significantly
lower population of CD138+ plasma cells compared to unmated
controls. The transmembrane marker CD138 is a syndecan
specifically found in plasma cells that has long been correlated
with the occurrence of chronic endometritis, an inflammatory
condition of the uterine lining often associated with negative
reproductive outcomes such as recurrent pregnancy loss,
implantation failure, and infertility (27, 28). The decrease in the
plasma cell population in the uterus, but not in the spleen or
lymph nodes, gives credence to clinical evidence that plasma
cell numbers should be at a tolerable level in the pregnancy
microenvironment (16). Thus, the lower plasma cell count is
likely suggestive of a normal implantation event.
The increased population of uterine B cells bearing CD80+
and CD86+ at day 5.5 pc is particularly interesting, as it implies
increased co-stimulatory function that may direct the T cell-
mediated immune response (29). Upregulation of CD80 and
CD86 expression on B cells is obtained by triggering and
activating the BCR through a variety of stimuli such as ligands
and cytokines (30, 31). Subsequently, the crosstalk facilitated by
the enhanced expression of these two co-stimulatory molecules
on activated B cells is capable of skewing T cell activity (29).
In pregnancy, it has been demonstrated that increased CD86
expression in murine peritoneal cavity B1-a B cells is associated
with perturbations to pregnancy in a CBA/J mice model, an
effect attributed to the increased capacity for Th1 and Th17
differentiation (32). It may however be a different case within
the pregnancy microenvironment as investigated here, where
the presence of the blastocyst and associated alterations in
cytokine production within the microenvironment may serve as
triggers for BCR activation and lead to enhanced expression of
both CD86 and CD80 on uterine B cells. Moreover, previous
studies demonstrated the upregulated expression of CD80 and
CD86 on murine splenic antigen presenting cells such as
dendritic cells and macrophages at the pre-implantation period
(day 3.5 pc). This was shown to be crucial in modulating T
regulatory cell (Treg) abundance, cytokine production, and
ultimately pregnancy outcome (33, 34). A follow up study
examining splenic B cells showed similar results, with CD86
protein expression significantly increased in normal pregnant
mice compared to abortion-prone models at pre-implantation
(35). Thus, we postulate that the differential expression of CD80
and CD86 in uterine B cells may be predisposing them to act in
a similar manner, that is elevated expression of these molecules
on uterine B cells may contribute to establishment of maternal
tolerance and therefore appropriate implantation. These findings
are certainly intriguing andwarrant further investigation that was
unfortunately, out of scope of this current study.
Amongst the B cell subsets, regulatory B cells or Bregs have
drawn attention as potentially critical players in pregnancy well-
being. Previous murine studies have shown that splenic Bregs
can rescue pregnancies in abortion-prone models (9), and a
clinical study has revealed that deficiency in circulating IL-10-
producing Bregs is correlated with higher risk of spontaneous
abortions (11). Furthermore, it was recently shown that the
lack of IL-10+ B cells in murine pregnancies led to diminished
embryo sizes and stagnated Treg pools, as well as increased
susceptibility to LPS which caused intrauterine fetal death
(36). With the expansion of uterine B cells at the peri-
implantation phase, we speculated whether these cells possessed
regulatory properties, and indeed demonstrated that uterine
B cells from day 5.5 pc pregnant mice effectively suppressed
syngeneic CD4+ T cell proliferation and activation as seen by the
significant reduction in proliferation and diminished expression
of the activation marker CD25 in a cell contact dependent
manner (Figure 3).
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FIGURE 6 | Phenotypic structure of an IL-10+ uterine B cell at peri-implantation. Schematic diagram of the phenotypic markers expressed by uterine IL-10+ B cells at
peri-implantation, including B cell receptors and markers (CD19, B220, IgM, IgD, MHC II), activation markers (CD27, CD38), differentiation markers (CD21, CD24),
co-stimulatory molecules (CD80, CD86), and IL-10 cytokine production.
Bregs are defined as any B cell carrying out negative regulation
of an immune response and as such, a plethora of studies have
attributed this ability to various subsets of B cells including
TIM-1+ B cells, PD-L1+ B cells, CD5+CD1dhi B cells, and
IL-10+ B cells (8). Among these subsets, only the IL-10+ B
cells were significantly expanded in the uterus at the peri-
implantation stage (day 5.5 pc) of pregnancy, with more IL-10
produced by B cells compared to non-pregnant controls and
splenic B cells (Figure 4). In pregnancy, IL-10 is found in high
amounts in placental and decidual tissues at early gestation
in pre-clinical and clinical studies and is well-established as
a vital cytokine for optimal pregnancy outcomes (37). Mainly
thought to be produced by trophoblasts, uterine natural killer
cells, monocytes, dendritic cells, and Tregs, IL-10 has been shown
to be a key cytokine for the balance of pro- and anti-inflammatory
signals that establish maternal immune tolerance during the
implantation process (38–40). While it was desirable to assess
the suppressive capacity of these uterine IL-10+ B cells on CD4+
T cells specifically, the low percentage of IL-10+ B cells (2–5%)
within an already scarce population of uterine B cells from an
individual pregnant mouse proved to be a major limitation to
conducting these experiments.
The molecular surface architecture of uterine IL-10+ B cells
is summarized in Figure 6 and illustrates how these cells may
facilitate their suppressive function. We determined that the
majority of uterine B cells isolated from pregnant mice at the
peri-implantation time point take on a phenotype descriptive
of mature and antigen-driven differentiated B cells: they bear
both IgM and IgD, antigen presenting cell marker MHC class
II, differentiation markers CD24 and CD21, and activation
marker CD38 (Supplementary Figure 4). The dual expression
of IgM and IgD is particularly interesting, as IgD co-expression
is suggested to indicate a “tolerogenic” role via regulating
autoreactivity brought about by chronic exposure to antigen
(6). Likewise, the retention of differentiation markers CD24 and
CD21 as well as expression of activation marker CD38 suggested
that uterine B cells are mature, but yet to have differentiated
into antibody-producing plasma cells (41, 42). Furthermore,∼20
and 50% of IL-10 negative uterine B cells express the ligands
CD80 and CD86, respectively (Figure 5B) which suggests that a
significant proportion of the uterine B cells have the capacity for
co-stimulating T cell activation, potentially leading to negative
regulation byway of Treg expansion andmodification of cytokine
production (33, 34). Interestingly, the small proportion observed
as IL-10+ B cells within the uterine B cell population exhibited
higher expression of co-stimulatory molecules CD80 and CD86
as well as CD27, an activationmarker of memory and plasmablast
lineages in murine B cells. In this study, these cell surface
molecules, together with the cells’ capacity for producing anti-
inflammatory IL-10, is likely to have contributed to the regulatory
phenotype that uterine B cells from pregnant mice exhibit.
The differential expression of these surface markers indicates
that IL-10+ B cells may be involved in facilitating changes in
the maternal immune network as it adjusts to the presence of
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fetal allo-antigens in early pregnancy. The increased capacity
and engagement of these activated IL-10+ B cells for T cell
co-stimulation potentially contributes to the range of the T cell
repertoire generated in early pregnancy, a process critical for
setting the conditions for implantation.
CONCLUSION
To our knowledge, this is the first comprehensive study on the
phenotype and functional characteristics of uterine B cells in
early murine allogeneic pregnancy. In this study, we demonstrate
an expanded pool of uterine B cells at the time points
associated with embryo implantation, which harbor expanded
subpopulations of CD80+CD86+ and IL-10+ B cells, which
collectively suppresses CD4+ T cell proliferation and activation.
Thus, we propose that at this crucial time point, B cells within the
uterine microenvironment undergo changes in both population
frequency and phenotype that supports a regulatory role and
contributes to the immune changes necessary for the progression
of a successful pregnancy.
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